Theralase Technologies Inc. · TSXV:TLT
Theralase Technologies — Investor Presentation (October 2026)
16 slides from Theralase Technologies's investor presentation, Oct 15, 2026
Slide 1: Corporate Presentation
Corporate Presentation TSXV:TLT | OTCQB:TLTFF October 15th, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 Forward-Looking Statements (“FLS”) contained in this presentation deal with the future revenue potential, business opportunities and/or strategic initiatives of Theralase® Technologies Inc. (“Theralase®” or the “Company”); including, information, analyses and/or projecti
Slide 3: Company
Company 3 Scientific and Pipeline Non-Muscle Invasive Management Team Intellectual Property Preclinical Research Primary Indication Bladder Cancer Extensive experience in:1 48 issued patents and 11 Energy-activated small molecules patents pending for small Non-Muscle Invasive Bladder Cancer Phase II
Slide 4: Strategic Objectives
Strategic Objectives 4 2026 • Complete patient follow-up for Study II • Compile clinical data for Health Canada and FDA review • Complete GLP toxicology for IV Rutherrin® 2027 • Achieve marketing approval of light-activated Ruvidar® for NMIBC in Canada and the United States • Commence Phase 0/I/II a
Slide 5: Ruvidar
Ruvidar® 5 • Ruthenium-based, synthetic energy-activated small molecule • Designed to “hunt and destroy” solid core tumours (bladder, brain, lung, pancreatic and colorectal)1 • Commercially manufactured with high yield and high purity (> 98%) • < 0.5 grams used for bladder cancer treatment 1) Kasple
Slide 6: Cancer
Cancer 6 Cancer cells become immortal through DNA damage (environmental, genetic or lifestyle factors), where they ignore the immune system signals to die, choosing to multiply into cancerous tumours that will kill the host, if not destroyed The trilogy of cancer treatment is surgery, chemotherapy a
Slide 7: Mechanism of Action
Mechanism of Action Visible or Near Infra Red Light, 7 Transferrin Radiation, Sound and/or Drug-Activated Receptor (“TfR”)2 Rutherrin + TfR 1O 2 Ruvidar® ROS Cancer cell destruction via Immunogenic Rutherrin®1 Cancer Cell Cell Death (“ICD”) activating the innate Ruvidar® Retained and adaptive immune
Slide 8: Bladder Cancer
Bladder Cancer 8 9th Most Common Cancer Worldwide Non-Muscle Invasive Bladder Cancer (“NMIBC”) 4th leading cancer in men 1 84,870 in US 1 Muscle Invasive Bladder 12,300 in Canada 2 Cancer (“MIBC”) 200,000 in Europe 3 614,298 in World 4 Patient Population: Bacillus Calmette-Guerin (“BCG”)-Unresponsiv
Slide 9: Study Design (Cohort 1)
Study Design (Cohort 1) 9 • Phase II clinical study enrollment completed (95 patients treated with light-activated Ruvidar®) • “One and Done” procedure, where the patient is provided the primary Study Procedure (1 hour of drug instillation, 1 hour of light activation) in an outpatient procedure. Com
Slide 10: Study Design (Cohort 2)
Study Design (Cohort 2) 10 • Phase II clinical study currently enrolling patients for treatment with light-activated Ruvidar® and Adstiladrin® • Complementary mechanisms of action (Ruvidar® target bladder cancer cells directly, Adstiladrin® targets health bladder cells to produce Interferon to stimu
Slide 11: Study Procedure
Study Procedure 11 Bladder cancer cells Ruvidar® instilled Ruvidar® localizes Green laser light destroyed by the in bladder via catheter preferentially inside activates Ruvidar® production of singlet demonstrating bladder cancer cells2,3 through fiber optics oxygen and / or Reactive absorption into
Slide 12: Patient Demographics
Patient Demographics1 12 AGE SEX RACE CIS + Ta STAGE PREVIOUS BCG THERAPY < 65 Female Non-White CIS + T1 6% TREATMENTS 18% 17% 16% <7 12% 2% ≥7 98% >= 65 Male White CIS 82% 83% 84% 82% Ruvidar® has demonstrated complete responses in patients, previously treated with and who failed therapy with: BCG,
Slide 13: Clinical Data (Interim)
Clinical Data (Interim)1 13 Primary Endpoint Performance (CR at any Point in Time) # % Confidence Interval (95%) Primary Endpoint Complete Response 58/89 65.2% [49.4, 80.9] ("CR") Total Response (CR 65/89 73.0% [56.4, 89.7] and IR) Secondary Endpoint Performance (Duration of CR) (450 Days) Secondary
Slide 14: FDA and Non-FDA Approved Drugs
FDA and Non-FDA Approved Drugs BCG-Unresponsive NMIBC CIS Drug Performance 14 90.0% 80.0% 70.0% 60.0% 50.0% International Bladder Cancer Group Guideline Non-FDA Approved 40.0% FDA Approved 30.0% Not uro-oncologist recommended 20.0% 10.0% 0.0% 0 3 6 9 12 15 18 21 24 27 30 33 36 39 1) Steinberg G et a
Slide 15: NMIBC Development Timeline
NMIBC Development Timeline 15 Milestone 2019 2020 2021 2022 2023 2024 2025 2026 2027 95 Patients Enrolled and Provided Primary Study Treatment FDA Fast Track Designation Patient Follow Up Premarket Approval (Study Device) Data Lock / Clinical Study Report Submission Health Canada and FDA Marketing A
Slide 16: Contact Information
Contact Information Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir. President and Chief Executive Officer rwhite@theralase.com, 416.699.5273 x 225 Arkady Mandel, M.D., Ph.D., D.Sc. Chief Scientific Officer Toll Free: 1.866.THE.LASE (843.5273) amandel@theralase.com, 416.699.5273 x 260 Work: 416.699.LAS
Theralase Technologies — Investor Presentation (October 2026) on 6ix